Inhibikase Therapeutics's total assets for Q1 2024 were $11.07M, a decrease of -38.10% from the previous quarter. IKT total liabilities were $4.29M for the fiscal quarter, a 49.90% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.